Women's Health News

RSS

G8 final communique draft shows agreement on maternal, child health initiative, funding amounts not yet set

A final communique draft completed last month for the upcoming G8 summit states that leaders will agree on a maternal health initiative that focuses on improving access to sexual and reproductive health services, including family planning, in the developing world, the Globe and Mail reports. The draft leaves "G8 countries free to decide whether their programs on reproductive health will fund abortions" (Clark, 6/4).

8 Jun 2010

U.N. Secretary-General, Sec. of State Clinton address Women Deliver conference

Governments worldwide should work with the U.N. on a joint action plan to significantly improve the health of women and children around the world by 2015, U.N. Secretary-General Ban Ki-moon said in a speech at the opening of the Women Deliver conference on Monday in Washington, DC, Agence France-Presse reports.

8 Jun 2010

30 percent of Aussie mums think it’s OK to drink alcohol while pregnant

A new Australian study has revealed an alarming trend showing one in three pregnant or breastfeeding woman are still drinking alcohol. The Alcohol Education and Rehabilitation Foundation (AERF) feel that in spite of warnings to pregnant women to cut out alcohol completely from their diets, many women are ignoring such warnings.

7 Jun 2010

Lawsuit to be launched over breast cancer gene patent

BRCA1 and BRCA2 are two genes that have been identified to hold a key to women’s susceptibility to get breast or ovarian cancer. Changes also known as mutations in these genes are significant in women who go on to develop breast or ovarian cancer. Melbourne-based company Genetic Technologies Limited (GTL) has the exclusive license from American biotechnology company Myriad Genetics to carry out testing for the genes in Australia. Myriad holds a patent for these genes.

7 Jun 2010

The Female Health Company granted U.S. Patent for FC2 Female Condom

The Female Health Company today announced that on June 1, 2010, the U.S. Patent office issued patent number U.S. 7,726,316 B1 for its second generation product, the FC2 Female Condom. In addition to the newly issued U.S. patent, Spain, Greece and Turkey recently issued patents on the FC2 Female Condom.

7 Jun 2010

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Chronix Biomedical today reported new data further demonstrating that its serum DNA blood tests have the potential to accurately detect early stage breast cancer and prostate cancer. Chronix's proprietary technology identifies disease-specific genetic fingerprints based on circulating DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells.

7 Jun 2010

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it presented positive efficacy and safety data for its doxorubicin targeted conjugate compound, AEZS-108, in ovarian cancer.

7 Jun 2010

Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting

Geron Corporation today announced the presentation of data from the clinical trial of imetelstat (GRN163L), the company's telomerase inhibitor drug, in combination with paclitaxel and bevacizumab in patients with breast cancer at the 2010 American Society of Clinical Oncology annual meeting in Chicago.

7 Jun 2010

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.

7 Jun 2010

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Amgen today announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer. The results are being presented for the first time in an oral presentation at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Newly reported results from a major clinical trial show that adding bevacizumab (Avastin) to standard frontline chemotherapy for women with advanced ovarian cancer and then continuing a maintenance dose of the drug afterwards significantly extends progression-free survival. Women receiving the new treatment regimen saw no worsening of their disease for 14.1 months, compared to 10.3 months for women receiving standard therapy.

7 Jun 2010

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Results of a Phase III study presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting showed that Eisai's eribulin mesylate significantly improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.

7 Jun 2010

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties.

7 Jun 2010

Endocyte presents interim results from phase II trial of EC145 plus Doxil for platinum-resistant ovarian cancer

Endocyte Inc., a company developing targeted small-molecule drug conjugates, will present results of an interim analysis from a randomized phase II clinical trial in women with platinum-resistant ovarian cancer on Sunday (June 6) during the 46th annual meeting of the American Society of Clinical Oncology in Chicago.

7 Jun 2010

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID® and Breast Cancer Index® molecular oncology tests. Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago.

7 Jun 2010

Incyte presents additional results from INCB7839 Phase I/II trial for HER2-positive metastatic breast cancer

Incyte Corporation announced today additional positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 66 patients with HER2-positive metastatic breast cancer during a poster session at the American Society of Clinical Oncology (ASCO) meeting in Chicago, IL, June 4 to June 8, 2010.

7 Jun 2010

Celldex Therapeutics reports mature data from CDX-011 Phase 1/2 study in advanced breast cancer

Celldex Therapeutics, Inc. today announced that mature results from a Phase 1/2 study evaluating CDX-011 in advanced stage breast cancer patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-011 is an experimental antibody-drug conjugate (ADC) directed against glycoprotein NMB (GPNMB) and linked to a potent cancer cell-killing drug, monomethyl-auristatin E (MMAE).

7 Jun 2010

Positive results from new analyses of denosumab Phase 3 trials

Amgen today announced positive results from several new analyses of two Phase 3 trials studying denosumab compared with Zometa® (zoledronic acid), the current standard of care, for the treatment of bone metastases in patients with advanced breast cancer ("136 study") and solid tumors or multiple myeloma ("244 study"). Results from these trials reinforce denosumab's consistent ability to delay the complications of bone metastases in patients with advanced cancer. These results are being presented during the 2010 American Society of Clinical Oncology Annual Meeting in Chicago.

5 Jun 2010

SOGC wants Canadian women to understand how sexual desire is more than just a feeling

Most Canadians would describe sexual desire as feelings of longing, craving, satisfying a sensuous appetite, or even the need for sensual indulgence. Today, the Society of Obstetricians and Gynaecologists of Canada wants to explain that desire is more than just a "feeling". The SOGC wants Canadian women to better understand the physical and psychosocial causes that may predispose to, precipitate or maintain a loss of desire.

5 Jun 2010

Multiple study data on Agendia's MammaPrint, BluePrint, and ColoPrint assays to be presented at 2010 ASCO

Agendia, a world leader in molecular cancer diagnostics, today announced that researchers from Agendia and leading academic centers in the U.S. and Europe will present data from multiple studies concerning Agendia's assays MammaPrint(R), BluePrint(TM), and ColoPrint(TM) at the American Society of Clinical Oncology Annual Meeting, June 4 - 8, 2010, at McCormick Place in Chicago. MammaPrint, the company's lead product, is the only FDA-cleared breast cancer recurrence test.

5 Jun 2010

Women's Health News

G8 final communique draft shows agreement on maternal, child health initiative, funding amounts not yet set

U.N. Secretary-General, Sec. of State Clinton address Women Deliver conference

30 percent of Aussie mums think it’s OK to drink alcohol while pregnant

Lawsuit to be launched over breast cancer gene patent

The Female Health Company granted U.S. Patent for FC2 Female Condom

Chronix's serum DNA assays have potential to detect early stage breast cancer, prostate cancer

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Clinical trial data of imetelstat in patients with breast cancer presented at ASCO annual meeting

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

AMG 386 demonstrates antitumor activity in Phase 2 trial involving patients with recurrent ovarian cancer

Bevacizumab extends progression-free survival in women with advanced ovarian cancer

Eisai's eribulin mesylate improves median OS compared with TPC in pre-treated metastatic breast cancer patients

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Endocyte presents interim results from phase II trial of EC145 plus Doxil for platinum-resistant ovarian cancer

bioTheranostics presents positive outcomes from CancerTYPE ID, Breast Cancer Index clinical studies

Incyte presents additional results from INCB7839 Phase I/II trial for HER2-positive metastatic breast cancer

Celldex Therapeutics reports mature data from CDX-011 Phase 1/2 study in advanced breast cancer

Positive results from new analyses of denosumab Phase 3 trials

SOGC wants Canadian women to understand how sexual desire is more than just a feeling

Multiple study data on Agendia's MammaPrint, BluePrint, and ColoPrint assays to be presented at 2010 ASCO

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Latest News